Skip to main content
. Author manuscript; available in PMC: 2018 Nov 1.
Published in final edited form as: Vaccine. 2017 Oct 9;35(46):6264–6268. doi: 10.1016/j.vaccine.2017.09.069

Figure 2. Poor IgG subtype responses toward PCV-13 in the context of VAD.

Figure 2

Serotype 4 (T4)-specific antibodies were evaluated by ELISA 10 days after a booster vaccine with PCV-13. OD readings for (A) IgG1, (B) IgG2b and (C) IgG3 are shown for VAD and control animals (N = 10 per group, N = 2 for naïve).